Navigation Links
Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
Date:11/6/2008

8 (p < 0.0001) and 20.7 at Week 16 (p = 0.02). Immune monitoring performed in three of four patients who underwent repeat treatment suggested an increase in immune response following the booster treatments. Five patients had prolonged disease stabilization ranging from 48 to 94 weeks, without the addition of other cancer therapy other than the continuation of bisphosphonates. In addition, one patient experienced a partial response lasting approximately six months.

"We were pleased to see consistent results across both NEUVENGE trials, particularly as they further substantiate the tolerability of this therapeutic approach," stated Mark Frohlich, M.D., senior vice president, clinical affairs and chief medical officer. "These data provide further evidence of the promise of our active cellular immunotherapy platform which also includes PROVENGE(R) (sipuleucel-T), our lead product candidate currently in late-stage development for prostate cancer. We expect to receive the final data analysis from our ongoing Phase 3 PROVENGE trial in mid-2009 and look forward to discussing further clinical development plans for NEUVENGE and our immunotherapy pipeline after that time."

About NEUVENGE

NEUVENGE (lapuleucel-T) is an investigational product in a new class of active cellular immunotherapies (ACIs) that are uniquely designed to stimulate a patient's own immune system. ACIs hold promise because they may provide patients with a meaningful clinical benefit with low toxicities. NEUVENGE is designed to stimulate cellular immune responses against HER2/neu. HER2/neu is over-expressed in a variety of solid tumors, including breast, colorectal, bladder and ovarian cancer. In clinical studies, patients typically received three infusions over a one-month period as a complete course of therapy.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commerc
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
7. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
8. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
9. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
10. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), a critical ... purification technology to help fight deadly inflammation in ... worldwide, today announced the appointment of Dr. ... its Senior Vice President of Clinical Development, effective ... Di Russo is an accomplished pediatric cardiothoracic ...
(Date:12/22/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ... Self-monitoring Blood Glucose Market" report to their offering. ... This market insight focuses on the developments in the ... States . Reimbursement analysis and the effects of ... more than 73 SMBG meters have been performed, based ...
(Date:12/22/2014)... Dec. 22, 2014  ConvaTec, a privately-held medical products ... been appointed Interim Chief Executive Officer of the company, ... Ken Berger .  "The Board of Directors of ... ConvaTec over the past three years," said Magnus ... "We are confident that the company is well positioned ...
Breaking Medicine Technology:CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
... , , , , IRVINE, Calif., Dec. 23 ... CO-Oximetry(TM) and Measure-Through Motion and Low Perfusion pulse oximetry, today announced ... J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in ... Time. A live audiocast of the presentation will be available ...
... , , , ... leading retail pharmacy, and MinuteClinic, the largest retail health care provider ... The H1N1 vaccine is expected to be widely available in ... from supplies distributed by public health authorities. , (Logo: ...
Cached Medicine Technology:Masimo to Present at the 28th Annual J.P. Morgan Healthcare Conference 2Masimo to Present at the 28th Annual J.P. Morgan Healthcare Conference 3CVS/pharmacy and MinuteClinic to Provide H1N1 Vaccinations Coast to Coast 2CVS/pharmacy and MinuteClinic to Provide H1N1 Vaccinations Coast to Coast 3CVS/pharmacy and MinuteClinic to Provide H1N1 Vaccinations Coast to Coast 4
(Date:12/25/2014)... December 25, 2014 Residents at ... Community, recently showed their generous spirit by providing ... Catawba County Parenting Network- Grandparents Raising Grandchildren program. ... gathered around the largest Christmas tree on the ... purchased by residents of the Abernethy Village Association ...
(Date:12/24/2014)... Wauwatosa, Wi (PRWEB) December 25, 2014 ... who are unable to afford certain items. During the holiday ... , "We collected over 70 toys," says Dr. Sara Mahalko-Leonhardt, ... myself and staff such joy, knowing that we are able ... any present had it not been for the generosity of ...
(Date:12/24/2014)... Dallas, TX (PRWEB) December 24, 2014 ... hormone specialist and functional medicine advocate with 30 years ... second trial to evaluate the health benefits of dietary ... January with new participants following excellent results from test ... , When asked to explain her interest in conducting ...
(Date:12/24/2014)... 24, 2014 New studies reveal that women ... loss related depression (March 6, 2014, JAMA Otolaryngology*). And although ... loss (about 50 percent according to recent polls) facing hearing ... how a person feels and relates to the world. People ... are also made by way of:, , ...
(Date:12/24/2014)... 2014 Today, UWDress.com, the famous women’s dress ... gowns, and launched a site-wide wedding gown promotion. ... gowns in a more unexpected way, the collection should be ... in the global market, and they are available with custom ... offered at discounted prices, up to 75% off; most of ...
Breaking Medicine News(10 mins):Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 2Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 4Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 5Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 6Health News:Buy Cheap Long Sleeve Wedding Gowns At UWDress.com 2
... ... started by people that were looking for an alternative to the high price of dental work ... have found that Mexican Dental Vacation is a great choice as a dental tourist destination. ... (PRWEB) December 4, 2009 -- After being ...
... , Dr. Redlener Applauds Historic Effort but ... Lost in Final Health Care Reform , NEW ... of Medicine today published a Perspective opinion piece ... Children,s Health Fund and Director, National Center for Disaster Preparedness ...
... many hesitate to take breast cancer drug, study finds , ... are a major reason why only 6 percent of American ... take the drug tamoxifen to prevent the disease, a new ... the risks and benefits of tamoxifen, researchers at the University ...
... , BOULDER, Colo., Dec. 4 ... , Kathryn Budig, a prominent yoga teacher, talks about her ... New Moon along the way. , To read, visit elephantjournal.com: ... CANCER , elephantjournal.com takes a look at one ...
... , JEFFERSON CITY, Mo., Dec. 4 Farmers Insurance Missouri ... Brad Ballard, the CEO and creator of a children,s fire safety ... will conduct a children,s fire safety day at the Missouri ... , "The call for fire safety comes following a tragic fire ...
... higher lifetime risk for another stroke, but several types of ... involves antithrombotic medications, otherwise known as blood thinners, of which ... But a new UCLA study to determine whether the ... seven-year period found that in each of the years, approximately ...
Cached Medicine News:Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3Health News:New England Journal of Medicine Perspective by Irwin Redlener, MD, Addresses Health Care Reform 2Health News:High-Risk Women May Often Avoid Using Tamoxifen 2Health News:Missouri Safety Day at the Capitol 2Health News:Are stroke survivors taking their medicine? 2
0.2 mm hook with curved shaft to reach over lens optic. Flat serrated handle with polished finish. Overall length: 4.8 inches. Most popular size or model....
0.2 mm, 90o angled tip with curved 9 mm shaft. Flat smooth handle with polished finish. Overall length: 4.5 inches....
Angled 45 degrees, 10 mm shaft with 0.2 mm tip. Round knurled handle with dull finish. Overall length: 4.6 inches....
2.0 mm cup. Angled 45 degree shaft 8 mm from tip to bend with flat handle and polished finish. Overall length: 4.8 inches....
Medicine Products: